New Jersey’s federal courts are in the midst of a surge in patent litigation, driven by pharmaceutical companies’ claims of infringement against generic-drug producers.
Plaintiffs filed seven patent suits in the District of New Jersey from May 20-26, representing a major escalation when compared with the average rate of one new patent suit per week. And the surge continued in the period from May 26-30, when another three patent suits were filed.
